Skip to main content
. Author manuscript; available in PMC: 2022 Feb 2.
Published in final edited form as: Nat Cancer. 2021 Aug 12;2(8):794–802. doi: 10.1038/s43018-021-00232-6

Extended Data Fig. 2. Predictive value of TLS status according to CPS PD-L1 scores.

Extended Data Fig. 2

Objective response rates (OR: objective response, SD: stable disease; PD: progressive disease; chi squared (χ2) test) and Kaplan-Meier curves of progression-free survival (log-rank test) and overall survival (log-rank test) of 328 cancer patients treated with anti-PD1/PD-L1 antagonists according to CPS PD-L1 scores (a: CPS PD-L1 <1, N=223 patients; b: CPS PD-L1 ≥ 1, N=105 patients) and TLS status (red curve: mature-TLS positive tumors; blue line: mature-TLS negative tumors).